Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.
Aug 31
40 min
Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.
Aug 17
47 min
Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.
Aug 3
43 min
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
Jul 20
40 min
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.
Jul 13
25 min
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Jul 6
31 min
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.
Jun 15
30 min
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.
Jun 8
55 min
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
May 31
39 min
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
May 30
41 min
Load more